Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, single-center experience.

Bortoluzzi I, Gambato M, Albertoni L, Mescoli C, Pacenti M, Cusinato R, Germani G, Senzolo M, Rugge M, Boccagni P, Zanus G, Cillo U, Burra P, Russo FP.

Transplant Proc. 2013 Sep;45(7):2707-10. doi: 10.1016/j.transproceed.2013.07.049.

PMID:
24034028
2.

High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.

Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.

J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):203-8. doi: 10.1097/MPG.0b013e3181819ad4.

PMID:
19179883
3.

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.

Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.

Liver Transpl. 2001 Jun;7(6):513-7.

4.

Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.

Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J.

Liver Transpl. 2002 Oct;8(10):892-900.

5.

Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.

Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL.

Clin Transplant. 2002 Dec;16(6):405-9.

PMID:
12437618
6.

Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.

Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E.

Gut. 2002 Jan;50(1):95-9.

7.

De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.

Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.

Liver Transpl. 2001 Jan;7(1):51-8.

8.

Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis.

Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE.

Transplantation. 2002 May 27;73(10):1598-602.

PMID:
12042646
9.

De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.

Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Zhu JJ, Wang SY, Qiu DK.

J Dig Dis. 2013 Aug;14(8):439-45. doi: 10.1111/1751-2980.12066.

PMID:
23638710
10.

Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results.

Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, Perrillo RP, Eason JD.

Clin Transplant. 2001;15 Suppl 6:55-8.

PMID:
11903388
11.

Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.

Pan JJ, Oh SH, Soldevila-Pico C, Nelson DR, Liu C.

Clin Transplant. 2011 Jan-Feb;25(1):164-70. doi: 10.1111/j.1399-0012.2010.01211.x.

12.

Liver grafts from anti-hepatitis B core positive donors: a systematic review.

Cholongitas E, Papatheodoridis GV, Burroughs AK.

J Hepatol. 2010 Feb;52(2):272-9. doi: 10.1016/j.jhep.2009.11.009. Epub 2010 Jan 19. Review.

13.

Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.

Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG.

Transplantation. 2003 Apr 27;75(8):1179-86.

PMID:
12717200
14.

Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts.

Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):475-80. doi: 10.1016/j.clinre.2014.03.016. Epub 2014 May 15.

PMID:
24835492
15.

Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.

Holt D, Thomas R, Van Thiel D, Brems JJ.

Arch Surg. 2002 May;137(5):572-5; discussion 575-6.

PMID:
11982471
16.

Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor.

Yu L, Koepsell T, Manhart L, Ioannou G.

Liver Transpl. 2009 Oct;15(10):1343-50. doi: 10.1002/lt.21788.

17.

The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.

Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH.

Liver Transpl Surg. 1997 Mar;3(2):105-11.

18.

De novo and apparent de novo hepatitis B virus infection after liver transplantation.

Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H.

J Hepatol. 1997 Mar;26(3):517-26.

PMID:
9075658
19.

Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients--5-year single-center experience.

Brandl A, Stolzlechner P, Eschertzhuber S, Aigner F, Weiss S, Vogel W, Krannich A, Neururer S, Pratschke J, Graziadei I, Öllinger R.

Transpl Int. 2016 Apr;29(4):471-82. doi: 10.1111/tri.12741. Epub 2016 Feb 1.

20.

Liver transplantation for hepatocellular carcinoma within Milan Criteria in patients with Model for End-Stage Liver Disease score below 15: the impact of the etiology of cirrhosis on long-term survival.

Tandoi F, Ponte E, Saffioti MC, Patrono D, Mirabella S, Lupo F, Romagnoli R, Salizzoni M.

Transplant Proc. 2013 Sep;45(7):2711-4. doi: 10.1016/j.transproceed.2013.07.002.

PMID:
24034029

Supplemental Content

Support Center